

## **Kişisel Bilgiler**

**İş Telefonu:** [+90 212 585 0007](tel:+902125850007)

**E-posta:** [bsakar@istanbul.edu.tr](mailto:bsakar@istanbul.edu.tr)

**Web:** <http://aves.istanbul.edu.tr/bsakar/>

## **SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler**

- I. **Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.**  
Dogan I., Tastekin D., Karabulut S., Sakar B.  
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021 (SCI İndekslerine Giren Dergi)
- II. **Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy**  
Aykan N. F. , Yildiz I., Sen F., Kilic L., Keskin S., Ciftci R., Karabulut S., Sakar B., Disci R.  
MEDICAL ONCOLOGY, cilt.30, sa.3, 2013 (SCI İndekslerine Giren Dergi)
- III. **Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey**  
Ustuner Z., Basaran M., Dizdar Y., Agaoglu F. Y. , Bilgic B., Sakar B., Basaran G. A. , Darendeliler E., Ozger H., Onat H., et al.  
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, cilt.213, sa.3, ss.221-229, 2007 (SCI İndekslerine Giren Dergi)
- IV. **A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas**  
Basaran M., Bavbek E. S. , Saglam S., Eralp L., Sakar B., Atalar A. C. , Bilgic B., Ozger H., Onat H.  
ONCOLOGY, cilt.72, ss.255-260, 2007 (SCI İndekslerine Giren Dergi)
- V. **The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients.**  
TAS F., USTUNER Z., CAN G., ERALP Y., CAMLICA H., BASARAN M., KARAGOL H., SAKAR B., DISCI R., TOPUZ E.  
Acta oncologica (Stockholm, Sweden), cilt.44, sa.2, ss.161-7, 2005 (SCI Expanded İndekslerine Giren Dergi)
- VI. **Ewing's sarcoma of the axial system in patients older than 15 years: Dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment**  
Argon A., Basaran M., Yaman F., Dizdar Y., Sakar B., Camlica H., Bavbek S. E. , Ozger H., Darendeliler E., Onat H.  
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, cilt.34, sa.11, ss.667-672, 2004 (SCI İndekslerine Giren Dergi)
- VII. **Clinicopathologic factors influencing survival of patients with bile duct and gallbladder carcinoma**  
Sakar B., Basaran M., Gumus M., Yazar A., Argon A., Aykan N. F.  
ANNALS OF ONCOLOGY, cilt.15, ss.243-244, 2004 (SCI İndekslerine Giren Dergi)
- VIII. **Colorectal cancer in young patients: Characteristics and outcome**  
Alici S., Aykan N., ŞAKAR B., Bulutlar G., Kaytan E., Topuz E.  
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, cilt.199, sa.2, ss.85-93, 2003 (SCI İndekslerine Giren Dergi)
- IX. **A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer**  
Başaran M., Bavbek S., Güllü İ., Demirelli F. H. , Şakar B., Tenekeci N., Altun M., Yalçın S., Onat H.  
JOURNAL OF CHEMOTHERAPY, cilt.14, ss.207-213, 2002 (SCI İndekslerine Giren Dergi)
- X. **Hypertrophic osteoarthropathy associated with docetaxel treatment.**  
Tas F., Aydinler A., Tenekeci N., Karadeniz A. N. , Sakar B., Topuz E.  
Clinical oncology (Royal College of Radiologists (Great Britain)), cilt.13, sa.2, ss.145-6, 2001 (SCI Expanded

## Diğer Dergilerde Yayınlanan Makaleler

- I. **A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma**  
Saglam S., Aykan N. F., ŞAKAR B., GÜLLÜOĞLU M., Balik E., Karanlık H.  
JOURNAL OF GASTROINTESTINAL ONCOLOGY, cilt.2, sa.1, ss.19-26, 2011 (ESCI İndekslerine Giren Dergi)

## Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?**  
Basaran M., KARABULUT S., KARABULUT M., GUNALDI M., ALIS H., Erturk K., Vatansever S., Sakar B., Aykan N. F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33
- II. **Prognostic roles of serum NEDD9 levels in patients with gastric cancer.**  
Karabulut S., Karabulut M., Alis H., Bozbey H. U. , Sakar B., Vatansever S., Aykan N. F.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33
- III. **Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC)**  
Keskin S., Sen F., AYDOĞAN F., Ekenel M., Kilic L., SAGLAM S., Sakar B., Disci R., AYKAN F.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30
- IV. **Opere lokal ileri mide kanserli hastalarda adjuvan kemoterapi ile kemoradyoterapinin etkinliğinin karşılaştırılması**  
ORDU C., KILIC L., EKENEL M., ŞAKAR B., AYKAN F.  
III. Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 24 - 28 Mart 2010, ss.121
- V. **Chemoradiotherapy in the adjuvant treatment of gastric cancer**  
Saglam E. K. , Ozturk B., Baskaya S., Saglam S., Sakar B., Yamaner S., Balik E., Oral E. N. , Kizir A., Aykan F.  
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.315-316

## Atıflar

Toplam Atıf Sayısı (WOS):136

h-ineksi (WOS):6